Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers - Test2 - elhamkhani - TriplyDB

Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers

Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers

http://www.wikidata.org/entity/Q24633883

about

Therapeutic benefits of a component of coffee in a rat model of Alzheimer's disease.The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy Alzheimer's disease and prion protein Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus Resveratrol acts not through anti-aggregative pathways but mainly via its scavenging properties against Aβ and Aβ-metal complexes toxicity Amyloid-β signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease.Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β.APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer's disease transgenic mice.Brain amyloid-β oligomers in ageing and Alzheimer's disease.Norovirus P particle-based active Aβ immunotherapy elicits sufficient immunogenicity and improves cognitive capacity in a mouse model of Alzheimer's disease.Lysosomal dysfunction in the brain of a mouse model with intraneuronal accumulation of carboxyl terminal fragments of the amyloid precursor protein.Small molecule microarrays enable the discovery of compounds that bind the Alzheimer's Aβ peptide and reduce its cytotoxicity.Therapeutic molecules and endogenous ligands regulate the interaction between brain cellular prion protein (PrPC) and metabotropic glutamate receptor 5 (mGluR5).Altered synaptic structure in the hippocampus in a mouse model of Alzheimer's disease with soluble amyloid-β oligomers and no plaque pathology Proneurogenic Group II mGluR antagonist improves learning and reduces anxiety in Alzheimer Aβ oligomer mouse.Early fear memory defects are associated with altered synaptic plasticity and molecular architecture in the TgCRND8 Alzheimer's disease mouse model.Cognitive and cortical plasticity deficits correlate with altered amyloid-β CSF levels in multiple sclerosis.Apomorphine and Alzheimer Aβ: roles for regulated α cleavage, autophagy, and antioxidation?Naproxen interferes with the assembly of Aβ oligomers implicated in Alzheimer's disease.High-resolution 3D reconstruction reveals intra-synaptic amyloid fibrils.Impaired β-amyloid secretion in Alzheimer's disease pathogenesis.CLU, CR1 and PICALM genes associate with Alzheimer's-related senile plaques.STIM2 protects hippocampal mushroom spines from amyloid synaptotoxicity.Presenilin 1 transgene addition to amyloid precursor protein overexpressing transgenic rats increases amyloid beta 42 levels and results in loss of memory retention.Neuronal Store-Operated Calcium Entry and Mushroom Spine Loss in Amyloid Precursor Protein Knock-In Mouse Model of Alzheimer's Disease.Physiologically generated presenilin 1 lacking exon 8 fails to rescue brain PS1-/- phenotype and forms complexes with wildtype PS1 and nicastrin.Critical role of intraneuronal Aβ in Alzheimer's disease: technical challenges in studying intracellular Aβ.The isotropic fractionator provides evidence for differential loss of hippocampal neurons in two mouse models of Alzheimer's disease.Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes.Zinc in the central nervous system: From molecules to behavior.Following activation of the amyloid cascade, apolipoprotein E4 drives the in vivo oligomerization of amyloid-β resulting in neurodegeneration.Evidence that small molecule enhancement of β-hexosaminidase activity corrects the behavioral phenotype in Dutch APP(E693Q) mice through reduction of ganglioside-bound Aβ.Dementia with Lewy Bodies: Molecular Pathology in the Frontal Cortex in Typical and Rapidly Progressive Forms.Mechanisms of neural and behavioral dysfunction in Alzheimer's disease.Aβ oligomer-induced synapse degeneration in Alzheimer's disease.Effect of amyloids on the vesicular machinery: implications for somatic neurotransmission.Phosphorylation of the amyloid β-peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity.Analyzing Nicotinamide Adenine Dinucleotide Phosphate Oxidase Activation in Aging and Vascular Amyloid Pathology.

P2860

Q24563378-A563C056-4018-4026-9CAB-60610F1EE4AA Q26747107-10441B6B-D979-406B-80EC-9EBF73D5D0A6 Q28250275-488B666A-2CB9-4D9E-A86A-3D135AD8D787 Q28397425-BFE67EEB-F9E9-4DE9-8748-D73CEF5BA25C Q28478772-F58DF158-8B61-45DD-B0B3-0CF3FFF93CEC Q30414554-352686F2-C4EA-4CA9-95BC-B8A19CE8C5BD Q30419992-E2BE6A9D-705B-41FC-907B-E6B9AA580EC1 Q30423789-2A2DD096-3893-42DA-85E7-23E6A19E7C64 Q30455082-3D29BFB9-3727-4A1A-AD9B-653C2AC84511 Q30497246-93A21E27-A9FD-4EF8-815C-86F6487B3E74 Q30539133-F38A8899-4C3D-4348-9773-3D2FB565DA53 Q30835636-F6BAD255-6098-4753-BC39-98EA6D7F2BBC Q33603071-85ACE328-A823-42E0-94C9-E40C8AD3D5E1 Q33742590-9261DD13-5FD6-4431-9A0D-A10F602DE13F Q34317403-5BF3130C-CAA5-4D9D-B0AB-4D92B60FCB89 Q34410122-6E49AF05-EAC1-41C3-B846-6F0451F684C9 Q34440691-05B27856-8301-47D1-9B67-479854C98AD3 Q34609073-865215B0-A52F-4ED0-B2CF-2641C4BDC0C3 Q34661859-74611123-CA72-4F67-90B3-4102A17CC7F1 Q34764667-F45DA66A-2476-466F-B0B5-81344499EAA0 Q34800804-4E123D07-0A3D-4D77-97E6-FC8F55199170 Q35474378-B25611F7-E7CD-42A8-9F1C-9A9FC4B44C34 Q35578470-98C015E2-2E14-4B06-87FC-89C76BD902A2 Q35579229-5A829AC1-3DB2-456D-A88D-CA9ECDEA48D5 Q35954470-E8821ECE-816D-4F31-AF29-9C422CF742B0 Q36070202-62E9517F-E544-4E75-940C-83B71A1BF596 Q36106832-363EFC51-BAEB-4F2E-9BD4-B04840CC1370 Q36320612-3B93ABFE-0AD9-4F0E-9C70-BB5C713C972D Q36342011-E2FDA5E0-2A7F-421A-9C1E-C37EA08AF7E2 Q36552324-29F1CBA9-0B9C-4513-BFA4-1D1F2383B76A Q36894417-8FD47AAE-13C9-4891-9E4C-7C64CADEFA57 Q37133159-9AEB6230-77EA-4C11-AD2C-AECB4F94A451 Q37313065-60F78607-94F5-46D7-9B63-6C3F0D6612AC Q37536299-A4285986-3EC2-4265-8CBC-68360C6236FE Q37694473-46141CF6-5372-40D1-9839-9F7AC98867A9 Q37855656-A13F866A-02A8-46F2-83D9-516571DAE49B Q37871455-8116400A-ADA7-4E14-9B00-8F30B58F6FCB Q38502400-C004F698-6A04-4B6A-A3B2-0FC00356A78C Q38959054-05AA07EB-411F-4FDF-B5EA-91B61A0045A4 Q40086374-FA3D9028-E89A-4384-B69F-FF8640EFD1C3

P2860

Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers

http://www.wikidata.org/entity/Q24633883

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Days to criterion as an indica ...... zheimer amyloid-beta oligomers

@ast

Days to criterion as an indica ...... zheimer amyloid-beta oligomers

@en

Days to criterion as an indica ...... zheimer amyloid-beta oligomers

@nl

type

label

Days to criterion as an indica ...... zheimer amyloid-beta oligomers

@ast

Days to criterion as an indica ...... zheimer amyloid-beta oligomers

@en

Days to criterion as an indica ...... zheimer amyloid-beta oligomers

@nl

prefLabel

Days to criterion as an indica ...... zheimer amyloid-beta oligomers

@ast

Days to criterion as an indica ...... zheimer amyloid-beta oligomers

@en

Days to criterion as an indica ...... zheimer amyloid-beta oligomers

@nl

P1433

Q24633883-70433855-8564-4B48-BA3E-4C05F6DA5AB0

P1476

Q24633883-829290F8-927C-4D02-AD38-8EC2A9C03BBD

P2093

Q24633883-090EEE93-D159-482D-A79B-899AF95734AB

Q24633883-2A3EAA5F-5B6B-469E-B6CD-6FE35E6DA733

Q24633883-3690DA23-1220-45E1-9C4B-96AC10FD1002

Q24633883-49B020BE-7EC0-4B36-A7AB-AEEA69F640B0

Q24633883-646323DD-A102-49D1-96FC-E724BD844756

Q24633883-8948F6D0-0F63-47B6-8ED6-BEBC4C9A1CDF

Q24633883-A3F29F4E-EE20-44BA-BD20-898AD23EC1CC

Q24633883-B0E7824A-F351-43A5-BA23-4A309263ED31

Q24633883-C6352236-C096-476D-94BE-E2B8468D548F

Q24633883-E4E33118-3284-4BAD-95DD-10D3F604B1C0

P2860

Q24633883-0FA9F7EC-A72C-4D0D-9A01-C8C6FABCD4B3

Q24633883-13148D28-0250-4609-8272-46C38EABEC1E

Q24633883-21DFC712-4A5E-4D2C-B6C4-DC9B12ED2757

Q24633883-21EFC6BA-8916-4AA3-8EAE-CC9FC0AAAF50

Q24633883-23B973EB-1E9E-4C76-A269-4A60B584D167

Q24633883-2CEECDAC-E163-40CF-8308-16928E48E19C

Q24633883-2F1E8E7E-5BF5-487E-9117-660092BB4B8B

Q24633883-2F21C363-16A7-439B-9AF0-47F6ED2BBE99

Q24633883-3360ADA3-99CF-478A-BB07-13A28CB5C82E

Q24633883-3493BFA1-79EA-4116-8B99-83F045F4D33B

P304

Q24633883-73AC9282-4BDC-46B1-B955-FB839C9690A0

P31

Q24633883-81821EF7-AD1C-43AF-9343-EE73913FDF79

P3181

Q24633883-434FD8B9-6D42-4915-BCDD-73ECEDA7ECC8

P356

Q24633883-FDB225F3-75DA-45D7-B992-516A21C983DA

P407

Q24633883-B488FAEE-4C2E-4D98-AB16-2921773F79F6

P433

Q24633883-C93092E3-9B04-40D0-8395-D60496B61482

P478

Q24633883-5609A04D-8883-49AF-B4EC-35AEA9724684

P50

Q24633883-02965382-A1C0-4A0A-AE44-514D0CDF7675

Q24633883-4821044B-4E5F-411C-A369-3ED7B0DCF07A

Q24633883-D5530A2E-7A8A-4DE0-B165-C7DB73C1B392

P577

Q24633883-021C71E5-620D-4E9C-95F4-343ACD043EE7

P5875

Q24633883-F009F4D2-5333-4E44-9BE9-A3A67ACC7F7F

P698

Q24633883-F347BD17-5CB9-4BEC-8B4F-F93CE5BFF522

P921

Q24633883-04897A42-6F33-4F1B-85DC-AE3FFABF0E52

P932

Q24633883-A8C30766-E583-4D9A-8225-11BF93542FE9

P3181

P356

P1433

Annals of Neurology

P1476

Days to criterion as an indica ...... zheimer amyloid-beta oligomers

@en

P2093

Adam J Simon

http://www.w3.org/2001/XMLSchema#string

Alex L Lublin

http://www.w3.org/2001/XMLSchema#string

Allan I Levey

http://www.w3.org/2001/XMLSchema#string

Charles Glabe

http://www.w3.org/2001/XMLSchema#string

Efrat Levy

http://www.w3.org/2001/XMLSchema#string

Grant A Krafft

http://www.w3.org/2001/XMLSchema#string

James J Lah

http://www.w3.org/2001/XMLSchema#string

James Schmeidler

http://www.w3.org/2001/XMLSchema#string

John W Steele

http://www.w3.org/2001/XMLSchema#string

Michelle E Ehrlich

http://www.w3.org/2001/XMLSchema#string

P2860

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior

Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake

Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway

A specific amyloid-beta protein assembly in the brain impairs memory

Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function

Take five--BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation.

Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques

Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations

The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease.

P304

220-230

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

193493

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/ANA.22052

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

Frédéric Checler

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45273084

http://www.w3.org/2001/XMLSchema#string

P698

20641005

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

3094694

http://www.w3.org/2001/XMLSchema#string